This is a preview of subscription content, log in via an institution to check access.
Notes
≥90% reduction in Psoriasis Area Severity Index score
2016 euros
References
Graham CN, et al. Cost-Effectiveness of Secukinumab in Moderate to Severe Psoriasis Compared with Other Biologics in Germany. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSS12, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71973?pdfid=49702.
Augustin M, et al. A Cost-Per-Responder Analysis of Secukinumab Compared with Ustekinumab Through 52 Weeks in Germany: Results from the Clear Study of Patients with Moderate to Severe Psoriasis. 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PSS15, 20 May 2017. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/71672?pdfid=49694.
Rights and permissions
About this article
Cite this article
Secukinumab cost effective for psoriasis in Germany. PharmacoEcon Outcomes News 780, 32 (2017). https://doi.org/10.1007/s40274-017-4084-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4084-7